Table 1.
Baseline characteristics of study participants.
| HIV-(N = 46) | HIV+(N = 39) | P-value | |
|---|---|---|---|
| Age (years) | 48.7 (±14.7) | 53 (±10.3) | 0.13 |
| Males | 18 (39.1%) | 15 (38.5%) | 1.00 |
| Body mass index (kg/m2) | 28.9 (25-32.7) | 27.3 (26.2-30.5) | 0.91 |
| Clusters of differentiation 4 count (cells/µl) | 705 (556-905) | 475 (359-738) | 0.001 |
| HIV viral load (copies/ml) | N/A | 0 (0-0) | N/A |
| On antiretroviral therapy | N/A | 33 (94.2%) | N/A |
| Fully vaccinated | 23 (50%) | 15 (38.5%) | 0.38 |
| Days since COVID-19 diagnosis | 74 (56-77) | 70 (56-91) | 0.49 |
| Hospitalized for COVID-19 | 24 (52.2%) | 31 (79.5%) | 0.012 |
| Comorbidities (diabetes, hypertension, and obesity) | 35 (76.1%) | 22 (56.4%) | 0.07 |
N/A, not applicable.
Among HIV-infected individuals, the total number with antiretroviral therapy status information was 35 out of 39. All continuous variables are presented as median and interquartile ranges.